- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02431416
Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty
Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Precocious Puberty
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with clinically suspected central premature puberty undergo a GnRH stimulation test to have an appropriate diagnosis. 20 such girls will be recruited to this study and a modified GnRH stimulation test will be done. The modification includes prolonged blood sampling time (0, 30, 60, 90, 120, and 150 min after the GnRH injection instead of the usual 0, 30, 60, and 90 min). The girls will also be investigated twice. In randomised order they will be given either GnRH or placebo (isotone saline), on different days. One week to one month will separate the different investigation days.
The proteinase inhibitor 4-(2-aminoethyl) benzene-sulfonyl fluoride hydrochlorid (AEBSF) will be added to some of the blood tubes, and hydrochloric acid will be added to some of the plasma. All plasma samples will be frozen and all analyses will be done at the same time. Acylated ghrelin will be analyzed by Millipore's specific ELISA kit and deacylated ghrelin will be analyzed by Cayman's specific ELISA kit.
Anthropometric data as well as pubertal state will be collected. P-glucose, S-insulin, S-follicle stimulating hormone (FSH), S-luteinizing hormone (LH), and S-estradiol will also be analyzed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Örebro, Sweden, 701 85
- Department of Paediatrics, Örebro University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female gender.
- Clinical suspicion of central precocious puberty.
- A GnRH stimulation test is to be performed to make appropriate diagnosis.
Exclusion Criteria:
- Age < 1 year.
- Weight < 10 kg.
- Untreated hypo- or hyperthyroidism.
- Diabetes of any kind.
- BMI > 3 z-score.
- Growth hormone treatment.
- Syndrome or suspected syndrome.
- Tumour or congenital malformation of the hypothalamus or the pituitary gland. (Neuroradiology does not have to be performed only because of the study.)
- On going ulcus ventriculi or the patient has gone through surgery that removed part of the ventricle or changed it markedly in any other way.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Gonadotropin releasing hormone (GnRH)
A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL).
Dose: 100 micrograms per square meter body surface.
Maximal dose: 100 micrograms.
|
Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
Other Names:
|
Placebo Comparator: Sodium chloride
A single intravenous injection of sodium chlorid (9 mg/mL).
Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
|
Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ghrelin concentration after GnRH injection and after saline injection
Time Frame: 30-150 min after iv injections
|
Paired comparison will be done between the acylated ghrelin concentration after GnRH injection and the acylated ghrelin concentration after saline injection. Paired comparison will also be done between deacylated ghrelin concentration after GnRH injection and deacylated ghrelin concentration after saline injection. |
30-150 min after iv injections
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Deacylated ghrelin concentrations in samples treated with the inhibitor AEBSF, in samples treated with both AEBSF and hydrochloric acid, and in samples not treated with either AEBSF or hydrochloric acid
Time Frame: At baseline
|
Concentrations of deacylated ghrelin will be compared between different handling procedures.
|
At baseline
|
Deacylated ghrelin concentrations in samples treated with the inhibitor AEBSF, in samples treated with both AEBSF and hydrochloric acid, and in samples not treated with either AEBSF or hydrochloric acid
Time Frame: 150 min after iv injections
|
Deacylated ghrelin concentrations will be compared at 150 min after iv injections between different handling procedures.
|
150 min after iv injections
|
Acylated ghrelin concentrations in samples treated with and without hydrochloric acid
Time Frame: 0-150 min after iv injections
|
Acylated ghrelin concentrations will be compared between different handling procedures.
|
0-150 min after iv injections
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Maria Lodefalk, MD, PhD, Department of Paediatrics, Faculty of Medicine and Health, Örebro University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OLL-430981
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Puberty, Precocious
-
AbbVieCompletedCentral Precocious Puberty (CPP)United States, Puerto Rico
-
Debiopharm International SARecruiting
-
Foresee Pharmaceuticals Co., Ltd.QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.RecruitingPuberty; Precocious, CentralUnited States, China, Taiwan, Puerto Rico
-
IpsenCompleted
-
TakedaCompletedCentral Precocious PubertyChina
-
TakedaCompletedCentral Precocious PubertyChina
-
Debiopharm International SACompletedCentral Precocious PubertyUnited States, Chile, Mexico
-
Ruijin HospitalShanghai Children's Hospital; Shanghai Children's Medical Center; Xin Hua HospitalCompletedCentral Precocious Puberty
-
Daewoong Pharmaceutical Co. LTD.CompletedCentral Precocious PubertyKorea, Republic of
-
University of PisaUnknownCentral Precocious PubertyItaly
Clinical Trials on Gonadotropin releasing hormone (GnRH)
-
Tanta UniversityCompletedInfertility | Intracytoplasmic Sperm Injection | Ovarian Reserve | GnRH AgonistEgypt
-
Massachusetts General HospitalCompletedKallmann Syndrome | Hypogonadotropic Hypogonadism | GnRH DeficiencyUnited States
-
Massachusetts General HospitalCompletedKallmann Syndrome | Idiopathic Hypogonadotropic Hypogonadism | GnRH DeficiencyUnited States
-
University Magna GraeciaCompletedEndometriosis | Pelvic Pain | Uterine Fibroids | Endometriosis of UterusItaly
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A.S, FranceTerminated
-
Ginegorama S.L.UnknownInfertility, Female | Ovulation Induction | In Vitro Fertilization (IVF) | OocytesSpain
-
Merck KGaA, Darmstadt, GermanyCompletedEmbryo Transfer | Luteal Hormone Supplementation in In-vitro FertilizationJapan
-
Stephanie B. Seminara, MDRecruitingHypogonadotropic HypogonadismUnited States
-
Stephanie B. Seminara, MDRecruitingHypogonadotropic Hypogonadism | Hypothalamic AmenorrheaUnited States